|

SGN-LIV1A Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: RO7235441, Ladiratuzumab vedotin

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

  • QuantumLeap Healthcare Collaborative1
  • Hoffmann-La Roche1

Indications

  • Breast Cancer2
  • Cancer2
  • Hormone Receptor Negative Tumor1
  • Hormone Receptor Positive Tumor1
  • Angiosarcoma1

Birmingham, Alabama1 trial

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

University of Alabama at Birmingham

Phase 2

Duarte, California1 trial

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

City of Hope

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.